The TransGlioma project aims to develop new therapies for glioblastoma via a cross-border translational research platform. The project started in September 2017 has a duration of 3 years, funded by the European Union under the Interreg-Italy-Slovenia program with a budget of 1.3 million euros, involving 3 research institutes, 2 health companies and 1 SME (small medium enterprise).
The project involves the capitalization of the results of the previous GLIOMA project (2007-2013) validating the prognoses of the biomarkers discovered in a wide range of cases to move on to the next phase which consists in identifying the best therapeutic approaches. The strengthening of this cross-border network will increase competitiveness in research and care. The planned outputs are open source software to analyze the data contained in the partner’s bio-banks and the identification of personalized drug targets for patients.
For more information, visit the project website TransGlioma .